

FIGURE 1

6607E0-T6FS9260

Anti-B-Galactosidase Antibody Response




FIGURE 2




FIGURE 3a




FIGURE 3b




FIGURE 3c

AACGTT: AATTGAACGTTTCGC
CTTGCAAGCGTTAA

FIGURES 3a-3c

09265191.031099



FIGURE 4

50µg DNA / week x 3 weeks
Measure antibody 4 weeks after first injection

660TED-16T59260

Anti-B-Galactosidase Antibody Response




FIGURE 5




FIGURE 6

CTL 12/13/95-2




FIGURE 7




FIGURE 8

09265191.031099

8/20

3 injection of pCMV-FRNP sc




FIGURE 9a

09265191.031099

9/20

Comparison of I.D. and I.M. gene Immunization

6607ED-T6T59260
O.D. 405 (1:2500)




FIGURE 9b

B Galactosidase Expression of Transfected Cos-1 cells




FIGURE 10

11/20

Effect of Intradermal Gene Immunization on Viral Challenge

660TED-T6T59260

SURVIVAL (MICE)




FIGURE 11

12/20

Kinetics of Anti Lac-Z IgG post Boosting (100mic Groups)




FIGURE 12

IgG 2a Response to Lac-Z (10mic Groups)




FIGURE 13

IgG 1 Response to Lac-Z (10mic Groups)




FIGURE 14

IgG 2a Response to Lac-Z post Boosting (10mic Groups)




FIGURE 15

IgG 1 Response to Lac-Z post Boosting (10mic Groups)




FIGURE 16

Anti Lac-Z IgE Response Post Boosting




FIGURE 17




FIGURE 18

09265191.031099